Thomas A. MCCOURT - 28 Feb 2022 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
Chief Executive Officer, Director
Signature
/s/ Brian Tessler, Attorney-in-Fact
Issuer symbol
IRWD
Transactions as of
28 Feb 2022
Net transactions value
-$521,526
Form type
4
Filing time
02 Mar 2022, 15:01:19 UTC
Previous filing
21 Jan 2022
Next filing
10 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Sale $20,915 -1,942 -0.31% $10.77 632,802 28 Feb 2022 Direct F1
transaction IRWD Class A Common Stock Sale $107,980 -10,026 -1.6% $10.77 622,776 28 Feb 2022 Direct F2
transaction IRWD Class A Common Stock Sale $215,077 -19,970 -3.2% $10.77 602,806 28 Feb 2022 Direct F3
transaction IRWD Class A Common Stock Sale $177,554 -16,486 -2.7% $10.77 586,320 28 Feb 2022 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
F3 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on February 27, 2020.
F4 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 22, 2021.